Inhibition of PCSK9 by monoclonal antibodies such as evolocumab prevents the degradation of low-density lipoprotein (LDL) receptors, leading to increased clearance of LDL cholesterol from the bloodstream.

Study: Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins.

The study tested a drug called evolocumab, which blocks a protein (PCSK9) that normally removes LDL receptors. With more receptors available, the body can clear bad cholesterol better—just like the claim says.

Study: PCSK9 Inhibition: From Current Advances to Evolving Future

The study explains that drugs like evolocumab block a protein (PCSK9) that normally destroys LDL receptors in the liver. With more receptors available, the body can remove bad cholesterol from the blood better, which matches the claim.

Study: PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects

The study shows that drugs like evolocumab block a protein (PCSK9) that normally destroys LDL receptors, so more receptors are available to remove bad cholesterol from the blood.

Study: The role of PCSK9 in heart failure and other cardiovascular diseases—mechanisms of action beyond its effect on LDL cholesterol

The study says that drugs like evolocumab block a protein called PCSK9, which lets the liver remove bad cholesterol from the blood better—exactly what the claim says.